Literature DB >> 28260130

Outcomes of postoperative stereotactic radiosurgery to the resection cavity versus stereotactic radiosurgery alone for melanoma brain metastases.

Giuseppe Minniti1,2, Sergio Paolini3, Giancarlo D'Andrea4, Gaetano Lanzetta3, Francesco Cicone5, Veronica Confaloni6, Alessandro Bozzao7, Vincenzo Esposito3, Mattia Osti6.   

Abstract

To investigate local control and radiation-induced brain necrosis in patients with melanoma brain metastases who received complete resection plus fractionated stereotactic radiosurgery (fSRS, 3 × 9 Gy) or fSRS alone. Factors associated with the clinical outcomes and the development of brain necrosis have been assessed. One hundred and twenty consecutive patients with 137 melanoma brain metastases who received surgery plus fSRS (S + fSRS) or fSRS alone were analyzed. All lesions evaluated in the study were treated with a dose of 27 Gy given in 3 fractions over three consecutive days. Cumulative incidence analysis was used to compare local failure (LF), distant brain failure (DBF), and radiation-induced brain necrosis (RN) between groups from the time of SRS. At a median follow-up of 13 months, median OS times and 1-year survival rates were comparable: S + fSRS, 14 months and 85%; fSRS, 12 months and 85% (p = 0.2). Median DBF did not differ significantly by group, being 14 months for both groups. Nine patients who received S + fSRS and 20 patients treated with fSRS recurred locally (p = 0.03). Six-month and 1-year LF rates were 5 and 12% in S + fSRS group and 17 and 28% in fSRS group (p = 0.02). RN occurred in 21 patients (S + fSRS, n = 14; fSRS, n = 7; p = 0.1). The cumulative 1-year incidence of RN was 13% after S + fSRS and 8% after fSRS (p = 0.15). In conclusion, postoperative SRS (3 × 9 Gy) to the resection cavity is an effective treatment modality for melanoma brain metastases associated with better local control as compared with fSRS alone.

Entities:  

Keywords:  Hypofractionated stereotactic radiosurgery; Melanoma brain metastases; Resection cavity; Stereotactic radiosurgery

Mesh:

Year:  2017        PMID: 28260130     DOI: 10.1007/s11060-017-2394-z

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  35 in total

Review 1.  Evolving treatment options for melanoma brain metastases.

Authors:  Thankamma Ajithkumar; Christine Parkinson; Kate Fife; Pippa Corrie; Sarah Jefferies
Journal:  Lancet Oncol       Date:  2015-10       Impact factor: 41.316

2.  Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases.

Authors:  Paul W Sperduto; Norbert Kased; David Roberge; Zhiyuan Xu; Ryan Shanley; Xianghua Luo; Penny K Sneed; Samuel T Chao; Robert J Weil; John Suh; Amit Bhatt; Ashley W Jensen; Paul D Brown; Helen A Shih; John Kirkpatrick; Laurie E Gaspar; John B Fiveash; Veronica Chiang; Jonathan P S Knisely; Christina Maria Sperduto; Nancy Lin; Minesh Mehta
Journal:  J Clin Oncol       Date:  2011-12-27       Impact factor: 44.544

3.  Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery.

Authors:  Francesco Cicone; Giuseppe Minniti; Andrea Romano; Annalisa Papa; Claudia Scaringi; Francesca Tavanti; Alessandro Bozzao; Riccardo Maurizi Enrici; Francesco Scopinaro
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-15       Impact factor: 9.236

4.  Fractionated stereotactic radiosurgery for patients with brain metastases.

Authors:  Giuseppe Minniti; Rolando M D'Angelillo; Claudia Scaringi; Luca E Trodella; Enrico Clarke; Paolo Matteucci; Mattia Falchetto Osti; Sara Ramella; Riccardo Maurizi Enrici; Lucio Trodella
Journal:  J Neurooncol       Date:  2014-02-01       Impact factor: 4.130

5.  Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery.

Authors:  Cheng Yu; Joseph C T Chen; Michael L J Apuzzo; Steven O'Day; Steven L Giannotta; Jeffrey S Weber; Zbigniew Petrovich
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-04-01       Impact factor: 7.038

6.  Hypofractionated stereotactic radiotherapy alone without whole-brain irradiation for patients with solitary and oligo brain metastasis using noninvasive fixation of the skull.

Authors:  Hidefumi Aoyama; Hiroki Shirato; Rikiya Onimaru; Kenji Kagei; Jun Ikeda; Nobuaki Ishii; Yutaka Sawamura; Kazuo Miyasaka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-07-01       Impact factor: 7.038

7.  Multidose stereotactic radiosurgery (9 Gy × 3) of the postoperative resection cavity for treatment of large brain metastases.

Authors:  Giuseppe Minniti; Vincenzo Esposito; Enrico Clarke; Claudia Scaringi; Gaetano Lanzetta; Maurizio Salvati; Antonino Raco; Alessandro Bozzao; Riccardo Maurizi Enrici
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-05-15       Impact factor: 7.038

8.  Resection followed by stereotactic radiosurgery to resection cavity for intracranial metastases.

Authors:  Ly Do; Richard Pezner; Eric Radany; An Liu; Cecil Staud; Benham Badie
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-10-14       Impact factor: 7.038

9.  Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Authors:  Antoni Ribas; Igor Puzanov; Reinhard Dummer; Dirk Schadendorf; Omid Hamid; Caroline Robert; F Stephen Hodi; Jacob Schachter; Anna C Pavlick; Karl D Lewis; Lee D Cranmer; Christian U Blank; Steven J O'Day; Paolo A Ascierto; April K S Salama; Kim A Margolin; Carmen Loquai; Thomas K Eigentler; Tara C Gangadhar; Matteo S Carlino; Sanjiv S Agarwala; Stergios J Moschos; Jeffrey A Sosman; Simone M Goldinger; Ronnie Shapira-Frommer; Rene Gonzalez; John M Kirkwood; Jedd D Wolchok; Alexander Eggermont; Xiaoyun Nicole Li; Wei Zhou; Adriane M Zernhelt; Joy Lis; Scot Ebbinghaus; S Peter Kang; Adil Daud
Journal:  Lancet Oncol       Date:  2015-06-23       Impact factor: 41.316

10.  Ipilimumab and radiation therapy for melanoma brain metastases.

Authors:  Ann W Silk; Michael F Bassetti; Brady T West; Christina I Tsien; Christopher D Lao
Journal:  Cancer Med       Date:  2013-10-10       Impact factor: 4.452

View more
  11 in total

1.  Comparison of Local Control of Brain Metastases With Stereotactic Radiosurgery vs Surgical Resection: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Thomas M Churilla; Imran H Chowdhury; Elizabeth Handorf; Laurence Collette; Sandra Collette; Yanqun Dong; Brian M Alexander; Martin Kocher; Riccardo Soffietti; Elizabeth B Claus; Stephanie E Weiss
Journal:  JAMA Oncol       Date:  2019-02-01       Impact factor: 31.777

2.  Does size matter? Investigating the optimal planning target volume margin for postoperative stereotactic radiosurgery to resected brain metastases.

Authors:  Jaymin Jhaveri; Mudit Chowdhary; Xinyan Zhang; Robert H Press; Jeffrey M Switchenko; Matthew J Ferris; Tiffany M Morgan; Justin Roper; Anees Dhabaan; Eric Elder; Bree R Eaton; Jeffrey J Olson; Walter J Curran; Hui-Kuo G Shu; Ian R Crocker; Kirtesh R Patel
Journal:  J Neurosurg       Date:  2018-04-20       Impact factor: 5.115

Review 3.  Five fraction stereotactic radiotherapy after brain metastasectomy: a single-institution experience and literature review.

Authors:  S Rogers; A Stauffer; N Lomax; S Alonso; B Eberle; S Gomez Ordoñez; T Lazeroms; E Kessler; M Brendel; L Schwyzer; O Riesterer
Journal:  J Neurooncol       Date:  2021-09-21       Impact factor: 4.130

4.  Long-term metabolic evolution of brain metastases with suspected radiation necrosis following stereotactic radiosurgery: longitudinal assessment by F-DOPA PET.

Authors:  Francesco Cicone; Luciano Carideo; Claudia Scaringi; Andrea Romano; Marcelo Mamede; Annalisa Papa; Anna Tofani; Giuseppe Lucio Cascini; Alessandro Bozzao; Francesco Scopinaro; Giuseppe Minniti
Journal:  Neuro Oncol       Date:  2021-06-01       Impact factor: 12.300

5.  Linac-based fractionated stereotactic radiosurgery for high-risk meningioma.

Authors:  Rahul N Prasad; John C Breneman; Timothy Struve; Ronald E Warnick; Luke E Pater
Journal:  J Radiosurg SBRT       Date:  2018

Review 6.  Radiosurgery dose reduction for brain metastases on immunotherapy (RADREMI): A prospective phase I study protocol.

Authors:  Shearwood McClelland; Tim Lautenschlaeger; Yong Zang; Nasser H Hanna; Kevin Shiue; Aaron P Kamer; Namita Agrawal; Susannah G Ellsworth; Ryan M Rhome; Gordon A Watson
Journal:  Rep Pract Oncol Radiother       Date:  2020-04-23

7.  Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.

Authors:  Giuseppe Minniti; Dimitri Anzellini; Chiara Reverberi; Gian Carlo Antonini Cappellini; Luca Marchetti; Federico Bianciardi; Alessandro Bozzao; Mattia Osti; Pier Carlo Gentile; Vincenzo Esposito
Journal:  J Immunother Cancer       Date:  2019-04-11       Impact factor: 13.751

8.  Serial examination of cardiac function and perfusion in growing rats using SPECT/CT for small animals.

Authors:  Tomo Hiromasa; Junichi Taki; Hiroshi Wakabayashi; Anri Inaki; Koichi Okuda; Takayuki Shibutani; Kazuhiro Shiba; Seigo Kinuya
Journal:  Sci Rep       Date:  2020-01-13       Impact factor: 4.379

Review 9.  Current status and recent advances in resection cavity irradiation of brain metastases.

Authors:  Giuseppe Minniti; Maximilian Niyazi; Nicolaus Andratschke; Matthias Guckenberger; Joshua D Palmer; Helen A Shih; Simon S Lo; Scott Soltys; Ivana Russo; Paul D Brown; Claus Belka
Journal:  Radiat Oncol       Date:  2021-04-15       Impact factor: 3.481

Review 10.  Management of brain metastasis. Surgical resection versus stereotactic radiotherapy: a meta-analysis.

Authors:  David T Krist; Anant Naik; Charee M Thompson; Susanna S Kwok; Mika Janbahan; William C Olivero; Wael Hassaneen
Journal:  Neurooncol Adv       Date:  2022-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.